Lead Product(s) : DIOS-HFVac3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DIOSynVax
Deal Size : Undisclosed
Deal Type : Partnership
ProBioGen Partners with DIOSynVax to Manufacture Trivalent Hemorrhagic Fever Vaccine
Details : The partnership aims to support the DIOSynVax product DIOS-HFVac3 vaccine for clinical advancement. It is being evaluated for the treatment of viral hemorrhagic fevers.
Product Name : DIOS-HFVac3
Product Type : Vaccine
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : DIOS-HFVac3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DIOSynVax
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1.2 million
Deal Type : Financing
smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics
Details : The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific team to further develop its innovative research platforms and identify novel solutions against multi-drug resistant p...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $1.2 million
Deal Type : Financing
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DIOSynVax
Deal Size : $42.0 million
Deal Type : Collaboration
Details : Ethris will design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs. This vaccine approach aims to provide protection from SARS-CoV-2 - the virus which causes COVID-19 dis...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 21, 2022
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DIOSynVax
Deal Size : $42.0 million
Deal Type : Collaboration
Lead Product(s) : FINCoVac 2.1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Rokote Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Rokote Laboratories Licenses Cevec’s Cap® Ad Technology For Vaccine Manufacturing
Details : Under the agreement, CEVEC has granted ROKOTE a non-exclusive rights to use the CAP® Ad platform for the manufacturing of adeno-based vaccines (FINCoVac 2.1) for prophylactic and therapeutic use in infectious diseases such as COVID-19, influenza and RSV...
Product Name : FINCoVac 2.1
Product Type : Vaccine
Upfront Cash : Undisclosed
September 20, 2022
Lead Product(s) : FINCoVac 2.1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Rokote Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : mRNA-based Shingles Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Pfizer Inc
Deal Size : $425.0 million
Deal Type : Collaboration
Details : The companies will leverage Pfizer's proprietary antigen technology and BioNTech's proprietary mRNA platform to develop mRNA based vaccine for Shingles. Pfizer will have rights to commercialize the vaccine gobally, except Germany, Turkey and certain deve...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $225.0 million
May 01, 2022
Lead Product(s) : mRNA-based Shingles Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Pfizer Inc
Deal Size : $425.0 million
Deal Type : Collaboration
Lead Product(s) : ETH47
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Laureus Capital
Deal Size : $26.3 million
Deal Type : Series B Financing
Details : The proceeds will advance the company’s lead programs ETH47 and ETH42, into clinical studies, further advance its proprietary and differentiated mRNA and lipidoid nanoparticle delivery platforms and increase its manufacturing capabilities.
Product Name : ETH47
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
January 02, 2022
Lead Product(s) : ETH47
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Laureus Capital
Deal Size : $26.3 million
Deal Type : Series B Financing
Lead Product(s) : DIOS-202,DIOS-203
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2
Details : Preclinical studies demonstrated that DIOS-202 and DIOS-203 selectively target two distinct epitopes of the SARS-CoV-2 spike protein at once, which largely prevents the emergence of escape mutants.
Product Name : DIOS-202
Product Type : Vaccine
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : DIOS-202,DIOS-203
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IM-250
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Life Sciences Partners
Deal Size : $23.7 million
Deal Type : Series A Financing
Innovative Molecules Raises €20 Million Series A Equity Financing Round
Details : The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study. IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) repli...
Product Name : IM-250
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 06, 2021
Lead Product(s) : IM-250
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Life Sciences Partners
Deal Size : $23.7 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : OntoChem
Deal Size : Undisclosed
Deal Type : Collaboration
OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie
Details : Anixa and OntoChem were seeking to develop an orally administrable, metabolically stable, non-toxic anti-viral therapy against SARS-CoV-2, the virus that causes Covid-19. Anixa is now working with MolGenie to use the generated compounds and data.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 05, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : OntoChem
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CV2CoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical data in rats immunized with CV2CoV in the dose range of 0.5-40µg demonstrated fast onset of strong immune responses already after the first dose.
Product Name : CV2CoV
Product Type : Vaccine
Upfront Cash : Inapplicable
May 13, 2021
Lead Product(s) : CV2CoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable